gout

News

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

News

Sobi plans filings for gout drug after phase 3 readout

SEL-212 will compete with Horizon's fast-growing Krystexxa if approved by the FDA.

News

AZ considers options as US gout drug deal backfires

Ironwood tears up licensing agreement after sales disappoint

News

FDA approves Ironwood's gout combination drug

Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.

News

Close-up image of a firm handshake between two colleagues

AZ sells US, EU and Latin America rights to gout drug

AZ focused on sales target set by CEO Pascal Soriot.

Sobi pays $1.5bn for Arthrosi to grow in gout

Sobi starts rolling FDA filing for chronic gout drug

Sobi plans filings for gout drug after phase 3 readout

AZ considers options as US gout drug deal backfires

FDA approves Ironwood's gout combination drug

AZ sells US, EU and Latin America rights to gout drug

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

gout

Editor's Picks